Collaborations A Long-Term Focus On Innovation

We welcome the opportunity to discuss:
Three scientists working together in a lab.
Business development collaborations

In-licensing and/or Research & Development (R&D) collaborations

  • Creative collaborations in emerging fields
  • Best-in-class technology platforms and capabilities to enhance the Regeneron antibody pipeline

Strategic late-stage development and commercial partnerships with other leading biopharma companies

Collaborations that maximize the global potential of our pipeline and ability to deliver new medicines to patients around the globe

Academic and research collaborations

Non-clinical research collaborations providing investigators from academic and research institutions access to our:

Learn more

Clinical collaborations/investigator-initiated studies (IIS) providing investigators and clinicians access to and/or funding for our:

Learn more
The Regeneron Genetics Center® (RGC) logo

The Regeneron Genetics Center® collaborates with experts from a large network of institutions to facilitate discovery that will transform patient care.

Learn about RGC Collaborations
Two employees looking at a document together.
Our business development strategy

Our entrepreneurial culture and history as one of the industry’s longest-standing biotech companies fosters a high-science mindset, nimble decision-making and highly collaborative relationships.

We follow the science, rather than limiting our innovations to any one therapeutic area. We are open to collaboration opportunities with the potential to offer important benefits to patients, representing a true scientific or medical advance. In particular, we consider:

  • Novel platforms that enable next-generation therapeutics
  • Technologies for antibody discovery and development against new/challenging targets
  • New approaches that enhance activity of tumor-directed antibodies
  • Biomarker discovery and validation
  • Drug delivery or formulation technologies that improve the efficacy/safety profile, address a CMC or supply challenge or enhance patient convenience or compliance
  • Studying the potential of combinations pairing our pipeline molecules with other innovative clinical-stage therapeutic candidates
  • Collaborations with leading academic groups to advance our efforts in human genetics, animal model development, target discovery, target validation and antibody discovery
Some of our current collaborations include:
Sanofi logo

Antibody and immunotherapy

BAYER logo

Global ophthalmology

Roche logo

Global manufacturing and distribution
collaboration for COVID-19 antibody
cocktail REGEN-COV

Intellia Therapeutics logo

Gene-editing technology

Alnylam Pharmaceuticals logo

RNA interference (RNAi)
therapeutics collaboration

Decibel Therapeutics logo

Collaborative gene therapy
programs for hearing loss

Columbia University logo

Research collaboration on genetic
basis of familial disease

Icahn School of Medicine at Mount Sinai logo

Antibody discovery

Biobank logo

Large-scale genetic research
and sequencing effort

to top